Myeloproliferative Neoplasms

Ruben A. Mesa; Ayalew Tefferi

doi:10.1002/9781444394016.ch3

Myeloproliferative Neoplasms

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.

Original language	English (US)
Title of host publication	Advances in Malignant Hematology
Publisher	Wiley-Blackwell
Pages	47-61
Number of pages	15
ISBN (Print)	9781405196260
DOIs	https://doi.org/10.1002/9781444394016.ch3
State	Published - Mar 24 2011

Keywords

Essential thrombocythemia
JAK2
Myeloproliferative
Polycythemia vera
Primary myelofibrosis

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1002/9781444394016.ch3

Cite this

@inbook{025c6c63c94a48949d65e061b5c6f553,

title = "Myeloproliferative Neoplasms",

abstract = "The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.",

keywords = "Essential thrombocythemia, JAK2, Myeloproliferative, Polycythemia vera, Primary myelofibrosis",

author = "Mesa, {Ruben A.} and Ayalew Tefferi",

year = "2011",

month = mar,

day = "24",

doi = "10.1002/9781444394016.ch3",

language = "English (US)",

isbn = "9781405196260",

pages = "47--61",

booktitle = "Advances in Malignant Hematology",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Myeloproliferative Neoplasms

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

PY - 2011/3/24

Y1 - 2011/3/24

N2 - The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.

AB - The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.

KW - Essential thrombocythemia

KW - JAK2

KW - Myeloproliferative

KW - Polycythemia vera

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84885567083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885567083&partnerID=8YFLogxK

U2 - 10.1002/9781444394016.ch3

DO - 10.1002/9781444394016.ch3

M3 - Chapter

AN - SCOPUS:84885567083

SN - 9781405196260

SP - 47

EP - 61

BT - Advances in Malignant Hematology

PB - Wiley-Blackwell

ER -

Myeloproliferative Neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this